EHF was identified as a GRHL2 target harboring a GRHL2 binding site in its promoter region that was conserved in all three luminal breast cancer cell lines (Fig. 3e; Additional files 6 and 8: Tables S1 and S2). Here, EHF is linked to breast carcinoma.